Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
Ali Raza KhakiAng LiLeonidas N DiamantopoulosMehmet Asim BilenVictor SantosJohn EstherRafael Morales-BarreraMichael DevittAriel NelsonChristopher J HoimesEvan ShreckHussein A AssiBenjamin A GartrellAlex SankinAlejo Rodriguez-VidaMark LythgoeDavid James PinatoAlexandra DrakakiMonika JoshiPedro Isaacsson VelhoNoah HahnSandy LiuLucia Alonso BuznegoIgnacio DuranMarcus MosesJayanshu JainJure MurgicPraneeth BaratamPedro BarataAbhishek TripathiYousef ZakhariaMatthew D GalskyGuru SonpavdeEvan Y YuVeena ShankaranGary H LymanPetros D GrivasPublished in: Cancer (2019)
Despite comparable ORRs, ICIs may not overcome the negative prognostic role of a poor PS, particularly in the first-line setting, and the initiation of ICIs in the last 30 DOL was associated with hospital death location.